United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc. ( PFE , Financial) posted first-quarter earnings on May 4 that far exceeded analysts' expectations and raised its full-year guidance.

Why Pfizer Is a Top Pick for Dividend Investors

BioNTech SE

Full FDA approval might not move the stock much, but it's still very important.

How Potential FDA Approval of Pfizer's COVID Vaccine Matters to Investors

Ford Motor Company

General Dynamics

Three great options for income-focused investors.

3 Dividend Stocks to Buy and Hold for the Long Term

It's worth buying into this first-in-class pharmaceutical.

Why Pfizer Is Still a Top Stock for 2021

Extending the gap between doses of the Pfizer–BioNTech COVID-19 vaccine from three to 12 weeks significantly boosts the antibody response in elderly people, according to a new U.K. study.

Delaying second Pfizer COVID shot boosts immune response in over-80s, study finds

There's still uncertainty about the big drugmaker's future COVID-19 vaccine revenue.

Why Pfizer Stock Didn't Soar After Its Fantastic Q1 Results

British public health officials say that this study vindicates their approach of prioritizing the rollout of the first dose while delaying the second shot.

Study Finds 12 Week Gap Between Pfizer Covid-19 Vaccine Dose Generates 3.5 Times Higher Antibody Response

The stock price of Pfizer Inc. (NYSE: PFE) increased by 1.03% today. This is why it happened.

Pfizer (PFE) Stock: 1.03% Increase Explanation

Pfizer (PFE)/BioNTech (BNTX) vaccine was 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.

Pfizer (PFE) COVID-19 Vaccine for Adolescents Endorsed by CDC

U.S. Covid case counts fell further on Wednesday, with the nationwide average now at about 36,700 per day over the past week, the lowest since Sept. 14.

U.S. Covid cases fall further as Pfizer's vaccine is cleared for 12- to 15-year-olds

A key CDC advisory committee has recommended that teenagers aged 12 to 15 receive Pfizer's Covid-19 vaccine. The guidance reaffirms the leading role of mRNA-based vaccines in fighting the pandemic.

CDC Panel Recommends Pfizer's Covid-19 Vaccine in Younger Teens. What Comes Next.

AstraZeneca

Adverse reactions were short-lived, with no other safety concerns, the researchers say.

Mixing Pfizer and AstraZeneca Vaccines Increases Mild Side Effects but Is Safe, Study Shows

The Centers for Disease Control and Prevention adopted the recommendation of a federal advisory committee that said the Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine is safe and effective for adolescents ages 12-15, opening the door for its widespread use starting today. The CDC panel met to discuss the merits of the vaccine in that age group after the FDA signed off Monday on the shots.

CDC Panel Backs Using Pfizer-BioNTech COVID-19 Vaccine For 12-15 Age Group

Mixing doses of COVID-19 vaccines increases the risk of mild to moderate side effects when compared with administering two shots of the same vaccine, according to a U.K. trial.

Mixing Pfizer and AstraZeneca COVID-19 vaccines increases mild side effects but is safe, study shows

Analysts aren't thinking about the near term -- they're thinking about 2026 and beyond.

Why Wall Street Is Worried About Pfizer Despite Its COVID Vaccine Success

Some of the recently mentioned threats to its bottom line are illusory, but inexperienced investors could still fall for an upcoming trap.

4 Things About Pfizer That the Smartest Investors Know

Adolescents across the US may be able to get the COVID-19 shot before week's end.

CDC panel approves Pfizer vaccine for children ages 12-15

President Joe Biden on Wednesday urged parents to get their children vaccinated after a key Centers for Disease Control and Prevention advisory panel endorsed the use of Pfizer's and BioNTech's Covid-19 vaccine for adolescents aged 12 to 15.

Biden urges parents to get kids vaccinated after CDC panel endorses Pfizer Covid vaccine

The Centers For Disease Control and Prevention gave Pfizer's COVID-19 vaccine the go ahead for use in teenagers from 12 to 15 years old on Wednesday. It means the vaccine could be put into the arms of middle and high schoolers across the country as early as Thursday. Her proclamation came after a full day of discussion, data dissection, and debate from the independent infectious disease experts who advise the CDC on how to use vaccines safely and ethically across the US.

CDC panel OK's Pfizer for 12- to 15-year-olds after safety review. Shots could go in arms tomorrow.

A Centers for Disease Control and Prevention committee voted 14-0-1 in favor of recommending that Pfizer Inc.'s COVID-19 vaccine can be safely used in 12 to 15 year olds. The recommendation, made Wednesday by the CDC's Advisory Committee on Immunization Practices, follows a similar regulatory pathway as the original emergency-use authorization awarded in December.

CDC committee recommends that Pfizer's COVID-19 shot be used in 12 to 15 year olds

The endorsement now awaits final approval by CDC Director Dr. Rochelle Walensky, which is expected imminently.

CDC panel endorses Pfizer's Covid vaccine for use in adolescents, clearing way for shots to begin Thursday

Amazon

Costco

Equinor

JPMorgan Chase & Co

Lockheed Martin

McDonald's

These safe stocks can be added to your portfolio to protect against rising inflation and the possibility of rate hikes in coming quarters. The post 7 Safe Stocks to Buy as Janet Yellen Talks Rate Hikes appeared first on InvestorPlace.

7 Safe Stocks to Buy as Janet Yellen Talks Rate Hikes

According to Reuters, Samsung BioLogics Co Ltd and Pfizer Inc (NYSE: PFE) have denied reports claiming they were working together to produce the COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) in South Korea. The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer/BioNTech vaccine.

Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters

States could begin administering shots in adolescents on Thursday, pending an endorsement from the CDC's Advisory Committee on Immunization Practices.

Five things to know before CDC panel votes on Pfizer's vaccine for use in adolescents

Moderna

Let's look to the long term for our answer.

News for Pfizer Stock (PFE)